01 diciembre 2015

JACC: CARDIOVASCULAR INTERVENTIONS. Changes in Left Atrial Appendage Dimensions Following Volume Loading During Percutaneous Left Atrial Appendage Closure

Ryan J. Spencer, MD; Peggy DeJong, MD; Peter Fahmy, MD; Mathieu Lempereur, MD; Michael Y.C. Tsang, MD; Kenneth G. Gin, MD; Pui K. Lee, MD; Parvathy Nair, MD; Teresa S.M. Tsang, MD; John Jue, MD; Jacqueline Saw, MD

Objectives: This study sought to determine whether volume loading alters the left atrial appendage (LAA) dimensions in patients undergoing percutaneous LAA closure.

01 diciembre 2015

JACC: CARDIOVASCULAR INTERVENTIONS. Regional Systems of Care to Optimize Outcomes in Patients Undergoing Transcatheter Aortic Valve Replacement

Dion Stub, MBBS, PhD∗,†; Sandra Lauck, PhD∗,‡,§; May Lee, MSc‖; Min Gao, MD, PhD‖; Karin Humphries, DSc‡,‖; Albert Chan, MD‡,¶; Anson Cheung, MD∗,‡; Richard Cook, MD∗,‡,#; Anthony Della Siega, MD∗∗; Jonathon Leipsic, MD∗,‡; Jay Charania, MD¶; Danny Dvir, MD∗,‡; Tim Latham, MD¶; Jopie Polderman, BSN§; Simon Robinson, MBChB, MD∗∗; Daniel Wong, MD¶; Christopher R. Thompson, MD∗,‡; David Wood, MD∗,‡,#; Jian Ye, MD∗,‡; John Webb, MD∗,‡,§

Objectives: This study sought to describe the development of a multicenter, transcatheter aortic valve replacement program and regional systems of care intended to optimize coordinated, efficient, and appropriate delivery of this new therapy.

01 diciembre 2015

JACC: CARDIOVASCULAR INTERVENTIONS. The Association of Previous Revascularization With In-Hospital Outcomes in Acute Myocardial Infarction Patients. Results From the National Cardiovascular Data Registry

Luis Gruberg, MD∗; Anne S. Hellkamp, MS†; Laine E. Thomas, PhD†; James A. de Lemos, MD‡; Benjamin M. Scirica, MD§; Anthony Hilliard, MD‖; Jonathan R. Enriquez, MD¶; Amr Mohsen, MD#; Tracy Y. Wang, MD, MHS, MSc†

Objectives: The aim of this study was to compare outcomes of ST-segment elevation myocardial infarction (STEMI) patients with a history of coronary artery bypass graft surgery (CABG), previous percutaneous coronary intervention (PCI), or no previous revascularization undergoing primary PCI.

01 diciembre 2015

JACC: CARDIOVASCULAR INTERVENTIONS. Effect of Ischemia Duration and Door-to-Balloon Time on Myocardial Perfusion in ST-Segment Elevation Myocardial Infarction. An Analysis From HORIZONS-AMI Trial (Harmonizing Outcomes with Revascularization and Stents in Acute Myocardial Infarction)

Abhiram Prasad, MD∗,†; Bernard J. Gersh, MB, ChB, DPhil∗; Roxana Mehran, MD‡,§; Bruce R. Brodie, MD‖; Sorin J. Brener, MD§,¶; José M. Dizon, MD#; Alexandra J. Lansky, MD∗∗; Bernhard Witzenbichler, MD††; Ran Kornowski, MD‡‡; Giulio Guagliumi, MD§§; Dariusz Dudek, MD, PhD‖‖; Gregg W. Stone, MD§,#

Objectives: This study sought to investigate the effect of treatment delay on microvascular reperfusion in ST-segment elevation myocardial infarction (STEMI) patients from the large, multicenter, prospective HORIZONS-AMI (Harmonizing Outcomes with Revascularization and Stents in Acute Myocardial Infarction) trial.

01 diciembre 2015

JACC: CARDIOVASCULAR INTERVENTIONS. Is There an Ideal Level of Platelet P2Y12-Receptor Inhibition in Patients Undergoing Percutaneous Coronary Intervention? “Window” Analysis From the ADAPT-DES Study (Assessment of Dual AntiPlatelet Therapy With Drug-Eluting Stents)

Ajay J. Kirtane, MD, SM∗,†; Puja B. Parikh, MD∗; Thomas D. Stuckey, MD‡; Ke Xu, PhD†; Bernhard Witzenbichler, MD§; Giora Weisz, MD∗,†,‖; Michael J. Rinaldi, MD¶; Franz-Josef Neumann, MD#; D. Christopher Metzger, MD∗∗; Timothy D. Henry, MD††,‡‡; David A. Cox, MD§§; Peter L. Duffy, MD, MMM‖‖; Bruce R. Brodie, MD‡; Ernest L. Mazzaferri, Jr., MD¶¶; Rupa Parvataneni, MS†; Akiko Maehara, MD∗,†; Philippe Généreux, MD∗,†,##; Roxana Mehran, MD†,∗∗∗; Gregg W. Stone, MD∗,†

Objectives: This study sought to determine whether there is an ideal level of platelet reactivity (PR) to optimize safety and efficacy within the large multicenter ADAPT-DES (Assessment of Dual AntiPlatelet Therapy With Drug-Eluting Stents) study of 8,582 patients receiving successful drug-eluting stent implantation.

01 diciembre 2015

JACC: CARDIOVASCULAR INTERVENTIONS. Limitation of Infarct Size and No-Reflow by Intracoronary Adenosine Depends Critically on Dose and Duration

Tuncay Yetgin, MD∗,†; André Uitterdijk, MSc∗; Maaike te Lintel Hekkert, BASc∗; Daphne Merkus, PhD∗; Ilona Krabbendam-Peters, BASc∗; Heleen M.M. van Beusekom, PhD∗; Robert Falotico, PhD‡; Patrick W. Serruys, MD, PhD∗; Olivier C. Manintveld, MD, PhD∗; Robert-Jan M. van Geuns, MD, PhD∗; Felix Zijlstra, MD, PhD∗,†; Dirk J. Duncker, MD, PhD∗,†

Objectives: In the absence of effective clinical pharmacotherapy for prevention of reperfusion-mediated injury, this study re-evaluated the effects of intracoronary adenosine on infarct size and no-reflow in a porcine model of acute myocardial infarction using clinical bolus and experimental high-dose infusion regimens.

01 diciembre 2015

JACC: CARDIOVASCULAR INTERVENTIONS. Effect of Drug-Coated Balloons in Native Coronary Artery Disease Left With a Dissection

Bernardo Cortese, MD∗; Pedro Silva Orrego, MD∗; Pierfrancesco Agostoni, MD, PhD†; Dario Buccheri, MD∗,‡; Davide Piraino, MD∗,‡; Giuseppe Andolina, MD‡; Romano Giuseppe Seregni, MD∗

Objectives: The authors sought to understand the clinical and angiographic outcomes of dissections left after drug-coated balloon (DCB) angioplasty.

01 diciembre 2015

JACC: CARDIOVASCULAR INTERVENTIONS. Pulmonary Artery Denervation Attenuates Pulmonary Arterial Remodeling in Dogs With Pulmonary Arterial Hypertension Induced by Dehydrogenized Monocrotaline

Ling Zhou, MD∗; Juan Zhang, MD∗; Xiao-Min Jiang, MD†; Du-Jiang Xie, MD∗; Jin-Song Wang, MD∗; Li Li, MD∗; Bin Li, PhD†; Zhi-Mei Wang, MD‡; Alexander M.K. Rothman, MD§; Allan Lawrie, PhD§; Shao-Liang Chen, MD∗,‡

Objectives: This study aimed to investigate sympathetic nerve (SN) ultrastructural changes and hemodynamic and pulmonary artery (PA) pathological improvements by pulmonary arterial denervation (PADN) in animals with pulmonary arterial hypertension (PAH), as well as the underlying mechanisms.

01 diciembre 2015

JACC: CARDIOVASCULAR INTERVENTIONS. How Can We Help a Patient With a Small Failing Bioprosthesis? An In Vitro Case Study

Prem A. Midha, MS∗; Vrishank Raghav, PhD∗; Jose F. Condado, MD, MS†; Sivakkumar Arjunon, PhD∗; Domingo E. Uceda, BS∗; Stamatios Lerakis, MD†; Vinod H. Thourani, MD†; Vasilis Babaliaros, MD†; Ajit P. Yoganathan, PhD∗

Objectives: The aim of this study was to investigate the hemodynamic performance of a transcatheter heart valve (THV) deployed at different valve-in-valve positions in an in vitro model using a small surgical bioprosthesis.

01 diciembre 2015

JACC: CARDIOVASCULAR INTERVENTIONS. Gluing of an Aortic Perforation During Transcatheter Aortic Valve Replacement. An Alternative Treatment for Annular Rupture?

Nicolas Piliero, MSc∗; Fréderic Thony, MD∗,†; Gerald Vanzetto, MD, PhD∗,‡; Gilles Barone-Rochette, MD, PhD∗,‡

A 96-year-old man was referred to our cardiology center for a transcatheter aortic valve replacement (TAVR). Pre-implantation transthoracic echocardiography showed preserved ejection fraction, mean transvalvular pressure gradient at 46 mm Hg, aortic valve area of 1 cm2, and maximal aortic jet velocity at 4.1 m/s, confirming severe aortic stenosis. Aortic annulus diameter was 25 mm as measured by transesophageal echocardiography, and its surface was 671 mm2 by 3-dimensional multidetector computed tomography

01 diciembre 2015

JACC: CARDIOVASCULAR INTERVENTIONS. Calcified Neoatherosclerosis Causing “Undilatable” In-Stent Restenosis. Insights of Optical Coherence Tomography and Role of Rotational Atherectomy

Teresa Bastante, MD; Fernando Rivero, MD; Javier Cuesta, MD; Fernando Alfonso, MD, PhD

We report a patient with undilatable in-stent restenosis (ISR) presenting 11 years after initial stent implantation. Optical coherence tomography (OCT) disclosed severe calcified neoatherosclerosis as the underlying substrate of ISR

01 diciembre 2015

JACC: Bioprosthetic Valve Thrombosis Versus Structural Failure. Clinical and Echocardiographic Predictors

Alexander C. Egbe, MD, MPH∗; Sorin V. Pislaru, MD, PhD∗; Patricia A. Pellikka, MD∗; Joseph T. Poterucha, DO∗; Hartzell V. Schaff, MD†; Joseph J. Maleszewski, MD‡; Heidi M. Connolly, MD∗

Background: Bioprosthetic valve thrombosis (BPVT) is considered uncommon; this may be related to the fact that it is often unrecognized. Recent data suggest that BPVT responds to vitamin K antagonists, emphasizing the need for reliable diagnosis.

01 diciembre 2015

JACC: Bioresorbable Vascular Scaffolds Versus Metallic Stents in Patients With Coronary Artery Disease. ABSORB China Trial

Runlin Gao, MD∗; Yuejin Yang, MD, PhD∗; Yaling Han, MD, PhD†; Yong Huo, MD‡; Jiyan Chen, MD§; Bo Yu, MD‖; Xi Su, MD¶; Lang Li, MD#; Hai-Chien Kuo, PhD∗∗; Shih-Wa Ying, MS∗∗; Wai-Fung Cheong, PhD∗∗; Yunlong Zhang, MD∗∗; Xiaolu Su, MS∗∗; Bo Xu, MBBS∗; Jeffery J. Popma, MD††; Gregg W. Stone, MD‡‡

Background: The everolimus-eluting bioresorbable vascular scaffold (BVS) is designed to achieve results comparable to metallic drug-eluting stents at 1 year, with improved long-term outcomes. Whether the 1-year clinical and angiographic results of BVS are noninferior to current-generation drug-eluting stents has not been established.

01 diciembre 2015

JACC: Quality-of-Life and Economic Outcomes of Assessing Fractional Flow Reserve With Computed Tomography Angiography. PLATFORM

Mark A. Hlatky, MD∗; Bernard De Bruyne, MD, PhD†; Gianluca Pontone, MD, PhD‡; Manesh R. Patel, MD§; Bjarne L. Norgaard, MD‖; Robert A. Byrne, MB BCh, PhD¶; Nick Curzen, BM (Hons), PhD#; Ian Purcell, MD∗∗; Matthias Gutberlet, MD††; Gilles Rioufol, MD‡‡; Ulrich Hink, MD§§; Herwig Walter Schuchlenz, MD‖‖; Gudrun Feuchtner, MD¶¶; Martine Gilard, MD##; Daniele Andreini, MD‡; Jesper M. Jensen, MD‖; Martin Hadamitzky, MD¶; Alan Wilk, BS∗∗∗; Furong Wang, MD∗∗∗; Campbell Rogers, MD∗∗∗; Pamela S. Douglas, MD§

Background: Fractional flow reserve estimated using computed tomography (FFRCT) might improve evaluation of patients with chest pain.

01 diciembre 2015

JACC: First-in-Man Experience of a Novel Transcatheter Repair System for Treating Severe Tricuspid Regurgitation

Francisco Campelo-Parada, MD∗; Gidon Perlman, MD†; François Philippon, MD∗; Jian Ye, MD†; Christopher Thompson, MD†; Elisabeth Bédard, MD∗; Omar Abdul-Jawad Altisent, MD∗; Maria Del Trigo, MD∗; Jonathon Leipsic, MD†; Philipp Blanke, MD†; Danny Dvir, MD†; Rishi Puri, MBBS, PhD∗; John G. Webb, MD†; Josep Rodés-Cabau, MD∗

Background: Isolated tricuspid valve surgery is associated with high morbidity and mortality, especially in patients with prior cardiac surgery. The transcatheter Forma Repair System (Edwards Lifesciences, Irvine, California) is designed to provide a surface for native leaflet coaptation to reduce tricuspid regurgitation (TR) by occupying the regurgitant orifice area.